Taletrectinib Hits 46-Month PFS in TKI-Naive ROS1+ NSCLC

At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Lyudmila Bazhenova, MD, presented updated pooled data from the TRUST-1 and TRUST-2 phase 2 trials evaluating taletrectinib (Ibtrozi), a central nervous system (CNS)-active ROS1 tyrosine kinase inhibitor (TKI). The analysis focused on TKI-naive patients with ROS1-rearranged metastatic non–small cell lung cancer (NSCLC), providing an additional 10 months of follow-up that further solidifies the drug’s efficacy and safety profile.

Efficacy and Durability

The pooled efficacy population included 157 patients, 23% of whom had brain metastases at baseline. The results demonstrated robust systemic and intracranial activity:

• Systemic ORR: The confirmed overall response rate (ORR) was 89.8%.
• Intracranial ORR: For patients with CNS involvement, the ORR was 76%.
• Progression-Free Survival (PFS): The median PFS reached 46.1 months.
• Duration of Response (DOR): The median DOR was 49.7 months.
• Overall Survival (OS): Median OS has not yet been reached, with 58.4% of patients alive at 48 months.

Safety Profile

The integrated safety analysis of 363 patients revealed no new signals. While laboratory abnormalities like increased AST (8.3% Grade 3) and ALT (11% Grade 3) occurred, most adverse events were Grade 1 or 2 gastrointestinal issues. Notably, taletrectinib showed a low incidence of neurologic toxicities—such as dizziness and dysgeusia—distinguishing it from other ROS1 TKIs. The discontinuation rate remained low at 8.5%.

Clinical Significance and Future Directions

Dr Bazhenova highlighted the importance of CNS penetration, noting that effective TKI therapy can delay the need for brain radiation and its associated cognitive side effects. Moving forward, she identified several priority areas for research:

1. Resistance Patterns: Identifying specific mutations that arise after taletrectinib treatment.
2. Combination Therapy: Exploring the benefit of combining the TKI with chemotherapy.
3. Early-Stage Setting: Investigating the role of taletrectinib in the adjuvant setting for resected early-stage ROS1-positive NSCLC.